Mosunetuzumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MOSUNETUZUMAB |
|---|---|
| Type | Drug |
| Aliases | LunsumioМосунетузумаб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-FL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | CD20×CD3 bispecific T-cell engager (full-length humanized IgG1) |
|---|---|
| Mechanism | Bispecific antibody binding CD20 on B-cells and CD3 on T-cells, forming an immune synapse that redirects polyclonal T-cell cytotoxicity against CD20+ B-cells. Step-up dosing schedule (1 mg → 2 mg → 60 mg → 30 mg) mitigates first-cycle CRS by limiting initial T-cell activation. Time-limited (8 cycles or until CR). |
| Typical dosing | Cycle 1: 1 mg IV day 1, 2 mg IV day 8, 60 mg IV day 15. Cycle 2: 60 mg IV day 1. Cycles 3-8: 30 mg IV day 1 of each 21-day cycle (total ≤8 cycles with extension to 17 cycles if not in CR by cycle 8). |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
GO29781 pivotal trial (Budde 2022): r/r FL after ≥2 prior lines including anti-CD20 + alkylator — ORR 80%, CR 60%, median DOR ~22.8 mo. Time-limited (max 17 cycles) — distinct from continuous BTKi paradigm. Ambulatory administration feasible after first cycle; hospital observation usually required for cycle 1 step-up doses. Major UA access barrier: not registered.
Used By
Regimens
REG-MOSUNETUZUMAB-FL- Mosunetuzumab IV step-up (8 cycles, 21-day; up to 17 if not in CR by C8) — r/r FL